Cargando…
HDAC Inhibition to Prime Immune Checkpoint Inhibitors
SIMPLE SUMMARY: Immunotherapy has made a breakthrough in medical oncology with the approval of several immune checkpoint inhibitors in multiple cancer types. Since only a minority of patients experience a durable response with these agents, combination strategies and novel immunotherapy drugs were d...
Autores principales: | Borcoman, Edith, Kamal, Maud, Marret, Grégoire, Dupain, Celia, Castel-Ajgal, Zahra, Le Tourneau, Christophe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750966/ https://www.ncbi.nlm.nih.gov/pubmed/35008230 http://dx.doi.org/10.3390/cancers14010066 |
Ejemplares similares
-
Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Borcoman, Edith, et al.
Publicado: (2021) -
Pembrolizumab in cervical cancer: latest evidence and clinical usefulness
por: Borcoman, Edith, et al.
Publicado: (2017) -
Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer
por: Borcoman, Edith, et al.
Publicado: (2020) -
Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019) -
Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma
por: Gougis, Paul, et al.
Publicado: (2019)